北京若生智能科技有限公司
Drug Database
LA

lamivudine + raltegravir (MK 0518B / Dutrebis / MK0518B)

✓ Approved

Merck & Co. · · 小分子

什么是 lamivudine + raltegravir？

lamivudine + raltegravir 是一种小分子，由Merck & Co.研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名MK 0518B, Dutrebis, MK0518B
公司Merck & Co.
药物类别小分子
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Merck & Co.

作用机制

分子靶点

lamivudine + raltegravir 作用于 1 个分子靶点：

gag-pol, HIV-1 (gag-pol)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

lamivudine + raltegravir 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsAcquired immunodeficiency syndrome✓ Approved

相关研究文献

PubMedACS applied materials & interfaces2026-09-10

Two Metal-Organic Frameworks Modified with Polyoxometalate for Efficient Visible-Light CO2 Reduction: From Covalent Nodes to Host-Guest Cages.

Zhao Yan Y, Yan Pin-Fang PF, Du Zu-Yu ZY, Mao Meng-Ge MG et al.

The urgent need to mitigate climate change has driven interest in photocatalytic CO2 reduction, yet traditional materials suffer from poor efficiency due to limited light absorption and rapid charge recombination. Polyoxometalate-based metal-organic frameworks offer a promising solution by combining the redox activity of polyoxometalate with the structural advantages of metal-organic frameworks. In this paper, two polyoxometalate-based metal-organic frameworks were synthesized under hydrothermal conditions: [Co(C7H8N4)2(H2O)][Co(C7H8N4)2](HBW12O40)·5H2O (BW12-Co) and Co1.5(C7H8N4)5(HSiW12O40) (SiW12-Co). BW12-Co is a chemically bonded framework where Keggin-type polyoxometalates serve as connecting nodes, while SiW12-Co features a host-guest architecture with polyoxometalate encapsulated within a zeolitic imidazolate framework. Both polyoxometalate-based metal-organic frameworks demonstrated exceptional performance as heterogeneous catalysts for the photoreduction of CO2. SiW12-Co achieved a remarkable CO generation rate of 12,673.98 μmol g-1 h-1 with 86.7% selectivity, surpassing most of the similar catalysts while maintaining excellent stability over six cycles. Their outstanding solvent stability and catalytic efficiency highlight the potential of polyoxometalate-based metal-organic frameworks for advanced applications in CO2 reduction.

PMID 42717448
阅读全文 →
PubMedFrontiers in public health2026-09-10

Clinical characteristics and prognostic factors in non-HIV patients with Pneumocystis jirovecii pneumonia and BALF cytomegalovirus co-detection: a retrospective cohort study.

Guo Chaomin C, An Yajiao Y, Ye Jingyun J, Ma Yanning Y et al.

Pneumocystis jirovecii pneumonia (PJP) is a life-threatening opportunistic infection in immunocompromised patients. BALF cytomegalovirus (CMV) co-detection is frequently observed in PJP patients, but its clinical characteristics and prognostic impact in non-HIV populations remain unclear. In this single-center retrospective cohort study, we enrolled 62 non-HIV patients with confirmed PJP between 2019 and 2023. BALF CMV co-detection was defined as detectable CMV DNA in bronchoalveolar lavage fluid via metagenomic next-generation sequencing (mNGS), combined with compatible respiratory symptoms and chest computed tomography abnormalities. The Benjamini-Hochberg false discovery rate (FDR) correction was applied for multiple comparisons. Overall, 31 patients (50.0%) had BALF CMV co-detection. The 28-day all-cause mortality was significantly higher in the CMV co-detection group than in the PJP-only group (54.84% vs. 19.35%, p = 0.008), and dyspnea was more prevalent (p = 0.024). After FDR correction for 39 laboratory parameters, only fibrinogen remained significantly lower in the co-detection group (q = 0.039), while (1,3)-β-D-glucan (BDG) and D-dimer showed independent associations with CMV co-detection in multivariable analyses. mNGS revealed more concurrent viral and fungal pathogens in the co-detection group, and multiple co-pathogens were more frequent in non-survivors within this subgroup. Interleukin-6 (IL-6), procalcitonin (PCT) and D-dimer were identified as independent prognostic factors for 28-day mortality in the CMV co-detection subgroup. In this single-center retrospective cohort, BALF CMV co-detection is associated with substantially elevated unadjusted 28-day mortality in non-HIV patients with PJP. These findings are hypothesis-generating; IL-6, PCT and D-dimer show potential as exploratory prognostic markers. Comprehensive mNGS-based pathogen screening combined with biomarker monitoring may facilitate risk stratification in this high-risk population, pending validation in larger prospective cohorts.

PMID 42719094
阅读全文 →
PubMedAlzheimer's & dementia : the journal of the Alzheimer's Association2026-09-10

TMEM106B is a selective modulator of TDP-43 pathology in Alzheimer's disease.

Reeves Madison M MM, Calliari Anna A, Todd Tiffany W TW, Maroto Cidfuentes Candela C et al.

Co-pathologies - including Lewy body, vascular, and TDP-43 lesions - are common in Alzheimer's disease (AD), contributing to its clinical and pathological heterogeneity. Genetic risk factors may drive mixed pathology presentation, but their influence on the development of specific co-pathologies remains unclear. We evaluated the TMEM106B coding variant rs3173615 and apolipoprotein E (APOE) diplotype (rs429358, rs7412) in post mortem brains from 2604 individuals with a primary neuropathologic diagnosis of AD. Binary logistic regression models linked each genetic modifier with co-pathology risk. The TMEM106B risk variant was significantly enriched in AD cases with transactive response DNA-binding protein 43 kDa (TDP-43) pathology - associating with increased odds of developing AD TDP-43 subtype α - but failed to associate with Lewy body or vascular pathology. In contrast, APOE ε4 associated with increased risk for multiple co-pathologies in AD. We find that genetic factors individually influence AD pathological heterogeneity: TMEM106B selectively modulates TDP-43 co-pathology, while APOE ε4 appears broadly permissive to co-pathology development.

PMID 42720122
阅读全文 →
PubMedHealth promotion international2026-09-10

A realist inspired barriers and facilitators evaluation of the co-creation process in the Youth-centred Participatory Action Project.

Souza Maria Fernanda S MFS, Chinapaw Mai M, Silva Catarina Santos CS, Demetriadou Leto L et al.

This study examined barriers and facilitators of the first phase of the co-creation process as part of the Youth-centred Participatory Action (YoPA) project, a multi-country co-creation initiative to address health inequities by engaging adolescents in Denmark, Nigeria, South Africa, and the Netherlands. Using a qualitative design informed by implementation science and realist thinking, we analysed data from 22 transcripts of semi-structured interviews with researchers, facilitators, and external stakeholders, alongside 61 logbooks from co-creation sessions. Data were coded deductively using the PROSECO process-evaluation framework, followed by the development of exploratory Context-Mechanism-Outcome configurations. Findings highlight four predominant areas shaping the co-creation process: group dynamics, partnerships, contextual influences, and resources and support. Facilitators included psychologically safe spaces, horizontal communication, consistent facilitation, strong institutional partnerships, motivation driven by purpose and belonging, and access to organizational resources and staff support. Barriers were associated with socioeconomic adversity, unstable infrastructures, logistical constraints, competing priorities, uneven engagement, and challenges in translating complex systems-thinking concepts into youth-friendly practice. Realist interpretations suggest that when structured participation, trust, and relational support were present, they activated mechanisms of ownership, agency, and sustained engagement; conversely, low-resource contexts and activities overload hindered participation, feasibility, and engagement. This study contributes empirical evidence on co-creation processes with adolescents across diverse settings. It demonstrates the combined value of the PROSECO framework and realist-inspired analysis for evaluation and understanding of how context and mechanisms shape co-creation in health-related research. Implications include the need for resourcing relational work, and designing context-sensitive strategies when conducting co-creation with adolescents.

PMID 42720508
阅读全文 →
PubMedOpen research Europe2026-09-10

Unlocking regional bioeconomy transitions: Co-creation, stakeholder engagement, and systemic change in rural Europe.

Hofer Margit M, Lindorfer Martina M, Gurgurovci Samire S

Transitioning to a sustainable bioeconomy in rural Europe is challenged by the difficulty of translating high-level strategies into locally relevant initiatives. Regional bioeconomy hubs aim to bridge this gap, but their success hinges on engaging diverse, often conservative, stakeholders. While co-creation is a promising approach, its practical application in these contexts is poorly understood. This study examines the establishment of nine hubs within the Horizon Europe project RuralBioUp to identify effective strategies for fostering stakeholder ownership and systemic change. This qualitative study analysed multi-layered data collected from nine regional bioeconomy hubs between October 2022 and June 2025. Sources included seven semi-structured interviews with hub facilitators, two mutual learning workshops, participatory feedback tools, and co-created documentation. Thematic analysis identified patterns related to effective actions, co-creation dynamics, and innovation adoption. Effective engagement actions were practical and locally grounded, such as study visits, targeted training in local languages, and co-organised events. Generic online workshops and bureaucratic activities proved ineffective. Co-creation was enabled by institutional flexibility, trusted local facilitators, and established networks. Key barriers included stakeholder time scarcity, logistical challenges, cultural scepticism, and unclear value propositions. In conservative settings, innovation adoption was facilitated through peer-to-peer learning and framing new ideas as extensions of existing practices. The success of regional bioeconomy hubs is contingent on trust, perceived local relevance, and stakeholder ownership, not just technological novelty. Instead of one-size-fits-all models, patient, bottom-up strategies that co-adapt innovation to community values are essential for long-term change. Hubs can act as critical facilitators for place-based transitions by embedding co-creation within flexible governance structures. Policy and practice should prioritize context-sensitive, tangible engagement to foster inclusive and sustainable rural bioeconomy development.

PMID 42718469
阅读全文 →
PubMedJournal of dual diagnosis2026-09-10

The Implementation of Current UK Guidance for the Treatment of Co-Occurring Mental Health and Substance Use Conditions: A Mixed Methods Systematic Review and Thematic Synthesis.

Swithenbank Zoe Z, Irizar Patricia P, Halsall Lauren L, Puddephatt Jo-Anne JA et al.

Background: Clinical guidance exists on the provision of care for co-occurring mental health and substance use conditions in the UK. This systematic review aimed to identify the extent to which the guidance has been applied, including barriers and facilitators to delivery, and to examine use of strategies to support implementation of the guidance. Methods: We searched PsychINFO, MEDLINE, CINAHL, Embase, and Web of Science for articles published between 1st January 2017 (when the guidance was published) to 28th January 2025. Studies were eligible if they focused on service use and/or treatment provision for adults in the UK with co-occurring substance use and mental health conditions. The findings were analyzed using a thematic synthesis, through line-by-line coding of study findings to develop analytical themes. Results: Three themes were identified from 17 eligible studies. Theme one reflects "challenges to care for co-occurring conditions", which describes how service users face 'wrong doors'; issues surrounding the recognition of co-occurring conditions; and access to care when and where it is needed, despite guidance recommending the 'no wrong doors' approach. Theme two reflects approaches for the "integration of care" as recommended in the guidance, such as communication across services and ensuring that support for people with co-occurring conditions is 'everyone's job'. The third theme highlights barriers (e.g., stigma) and facilitators (e.g., therapeutic optimism) to applying the guidance. Conclusion: This review identified an implementation gap between best practice guidance and the provision of care for co-occurring conditions in the UK setting, which needs to be explored across a global context. There were positive examples of strategies to implement the guidance, particularly from small-scale intervention evaluations, yet studies of larger scale real-world intervention implementation are needed.

PMID 42720452
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多lamivudine + raltegravir